Smart Equity Invest

← Results dashboard

Q2 FY27 · NSE: NAVINFLUOR

Navin Fluorine International

Results filed 30 October 2026 · Market cap ₹44,541 crore · PE 48.6

GrowthGuidance maintainedTranscript read

Revenue
+57.0%
on a year ago
EBITDA
+65.5%
on a year ago
Profit to shareholders
+81.5%
on a year ago
EBITDA margin
34.2%
+0.1 pts on last quarter

Navin Fluorine reported strong Q2 FY27 results with consolidated revenue advancing 57% YoY to INR 1,191 crores and operating EBITDA margins expanding to 34.2%. Growth was supported by an extension of the Solstice HFO contract through 2032 adding ~USD 180 million, alongside ramping MPP debottlenecking and a 78% YoY surge in CDMO. Key future catalysts include commissioning of the R32 expansion, Chemours liquid cooling plant in Q3 FY27, and Phase II cGMP-4 in Q4 FY27 within an annual capex framework of INR 700-1,000 crores.

Navin Fluorine International Limited, Q2 FY27₹ crore, consolidated
Q2 FY27Q1 FY27vs previous quarterQ2 FY26vs a year ago
Revenue1,1911,045+13.9%758+57.0%
Operating profit (EBIT)365315+15.6%210+74.0%
Operating margin30.6%30.2%+45 bps27.6%+299 bps
Other income15.635.09−55.5%18.21−14.3%
Exceptional items00–0–
Profit before exceptional items and tax352318+10.4%198+78.0%
Profit to shareholders269243+10.7%148+81.5%
Share of joint ventures' and associates' profit−0.010n.m.0n.m.
Earnings per share (₹)52.4847.45+10.6%29.06+80.6%

Source: Navin Fluorine International Limited’s filing to NSE, 30 October 2026. Operating profit is revenue less every expense except interest, so it leaves out other income and exceptional items. n.m.: not meaningful, because the earlier figure was zero or negative, or the latest one is a loss.

What stood out

  • Solstice HFO supply contract extended by 4 years with ~USD 180 million incremental revenue potential
    SourceThe tenure of our existing HFO supply contract with Solstice Advanced Materials has been extended by 4 years until December 2032 and will have an additional revenue potential of approximately USD180 million (Transcript page 3-4, Vishad Mafatlal; Presentation page 7)
  • Strong broad-based quarterly financial performance with consolidated revenue surging 57% YoY and operating EBITDA expanding to 34.2%
    SourceOperating revenue for the quarter stood at INR1,191 crores, registering a year-on-year growth of 57%. Operating EBITDA grew by 66% year-on-year to INR407 crores, with margins expanding to 34.2% (Transcript page 5-6, Anish Ganatra; Presentation page 5)
  • CDMO revenue jumped 78% YoY and management reiterated reaching a USD 100 million order book run rate
    SourceCDMO revenue grew 78% YoY to Rs. 239 Cr (Presentation page 5, 9); 'we are at the striking distance of our USD100 million target in terms of order book visibility' (Transcript page 7, Anish Ganatra)

Guidance

MetricGuidancePeriod
Operating EBITDA Margin
SourceFor this year itself, for FY27... we are going to be working on the margins that you see for the first half in the same sort of range for the year... We are not going to change the guidance from 30% [long-term] (Transcript page 12, Anish Ganatra)
Around ~34% for FY27 (in the same range as H1 FY27); maintaining long-term base guidance of 30%FY27 & Long-term
Annual Capex Framework
SourceOur capex frame will be in the INR700 crores to INR1,000 crores every year. INR700 crores this year is what we are looking at (Transcript page 11, 13, Anish Ganatra)
INR 700 to INR 1,000 crores annually; FY27 at lower end around INR 700 croresFY27 and annual frame
Specialty Chemicals Quarterly Run-rate
SourceINR350 crores as a run rate, we have said about last 3 quarters... And it will go up because of the reasons we talked before (Transcript page 6, 10, Anish Ganatra)
INR 350 crores base run-rate with further upside from debottleneckingH2 FY27
CDMO Revenue
SourceCDMO, of course, like we said... we are at the striking distance of our USD100 million target in terms of order book visibility (Transcript page 7, Anish Ganatra)
Target of USD 100 million order book visibility by FY27 on trackFY27

Maintained annual capex frame (INR 700-1,000 Cr) and long-term 30% margin threshold, while upgrading FY27 margin expectations to remain near H1 level of ~34%.

Tailwinds

  • Favorable refrigerant pricing and high merchant volume placement in AHF
    SourceHPP business grew sequentially and YoY from pricing advantage in ref gases and increased AHF volumes beyond planned captive consumption (Transcript page 6, 12, Anish Ganatra)
  • Operational efficiency and multi-product mapping in Specialty MPP
    SourceDebottlenecking of MPP at Dahej commissioned in September 2026; MPP-1 and MPP-2 expected to far exceed PAR (Transcript page 7, 14, Anish Ganatra; Presentation page 8)
  • Strong CDMO expansion via European major (Fermion) and molecule pipeline maturation
    SourceIncreasing demand for existing molecules and qualification PO received; two molecules progressing positively including China approval and US FDA fast track (Transcript page 5, 9, 11; Presentation page 9)

Headwinds

  • Raw material cost inflation across fluorspar, sulfur, and gas
    SourcePrices for sulfur, gas, and fluorspar have gone up, pressuring gross margins which fell 186 bps YoY on consolidated basis (Transcript page 10, Anish Ganatra; Presentation page 12)
  • Customer pricing dynamic in extended HFO contract indicates lower annual dollar run rate
    SourceAnalysts highlighted implied USD 45 million annual run rate for the 4-year USD 180 million extension vs historical ~USD 58-60 million, due to pass-through commercial structuring (Transcript page 8, Sanjesh Jain and Rohit Nagraj)

New businesses and products

partnership · Targeted commissioning in Q3 FY27; POs in hand for delivery in Q4 FY27

Chemours Liquid Cooling Project

Expected benefit
Enable entry into emerging advanced liquid cooling / hypercomputing market
Risks
Technology qualification and adoption timelines across OEM architectures take ~15 months post commissioning
Timeline
Commissioning in Q3 FY27, deliveries start Q4 FY27
Investment
INR 120 crores (35% customer-funded, 65% internal accruals)
SourcePresentation page 11; Transcript page 4, 9, 13 (Vishad Mafatlal, Anish Ganatra)

capacity expansion · Under execution, commissioning shortly and ramping up in Q3/Q4 FY27

Additional HFC Capacity (R32)

Expected benefit
Peak annual revenue potential of INR 600-825 crores across 15,000 MTPA R32 capacity
Risks
Geopolitical volatility and commodity pricing shifts
Timeline
Commissioning shortly; full ramp-up by Q4 FY27
Investment
INR 236.5 crores funded by internal accruals
SourcePresentation page 7, 11; Transcript page 4, 7 (Vishad Mafatlal, Anish Ganatra)

new business · Under execution

Advanced Materials Adoption Capacities

Expected benefit
Incubating new vertical targeting niche applications in Data Centers, Electronics, Defense & Semiconductors, projected to be 10-15% of business by 2030
Risks
Adoption cycles and qualification lead times
Timeline
Completion by Q2 FY28
Investment
INR 90 crores
SourcePresentation page 10, 11; Transcript page 4, 14 (Vishad Mafatlal, Anish Ganatra)

capacity expansion · Under construction, on schedule

Phase II cGMP4 Facility

Expected benefit
Dedicated plant for Fermion with ~3x asset turnover (peak revenue potential INR 900-1,000 crores along with Phase 1 by FY28/29)
Risks
Customer concentration (dedicated single client)
Timeline
End of Q4 FY27
Investment
INR 125 crores
SourcePresentation page 9, 11; Transcript page 4, 11 (Vishad Mafatlal, Anish Ganatra)

new product · In progress per schedule

DRDO TDF Project (Critical Defense Material)

Expected benefit
Dual-use specialty material with domestic pharma market alone of ~INR 400 crores at 50% share
Risks
Extended qualification timelines from defense authorities
Timeline
Not explicitly stated; progressing per schedule
Investment
Not specified
SourcePresentation page 10; Transcript page 4, 10 (Vishad Mafatlal, Anish Ganatra)

other · Investment underway

Renewable Hybrid Power Plant SPV

Expected benefit
14.9 MW hybrid capacity meeting >60% of plant energy requirements through renewables
Risks
Project implementation delays
Timeline
Not specified
Investment
INR 15.73 crores across NFIL & NFASL
SourcePresentation page 11; Transcript page 4 (Vishad Mafatlal)

How the call went

The call offered robust detail on project commissioning timelines and pipeline progress across Specialty and CDMO, balanced by firm pushback on commercially sensitive metrics and utilization percentages.

Specific or vague
Management provided clear timelines for capex (R32, Chemours, cGMP4 Phase 2), capital outlay ranges, and target run rates, though remained non-disclosing on utilization rates and Chemours economics under NDA.
Candour
CFO was candid about geopolitical risks, raw material cost inflation (sulfur, gas, fluorspar), and contract structures, though was somewhat defensive on the definition of 'dedicated plants' and exact utilization numbers.
The hard questions
Analysts pressed heavily on the implied run rate drop in the HFO contract extension (USD 45m vs USD 60m), Chemours project delay, and exact plant capacity utilization figures.

What analysts pressed on

  • Lower revenue run rate on the extended 4-year HFO contract with Solstice compared to historical 7-year run rate
  • Timeline and commercial qualification risks for Chemours advanced liquid cooling project
  • Gross margin protection sustainability amidst rising raw material costs (fluorspar, sulfur)

Answers that sidestepped

  • Refusal to share exact AHF utilization rates: 'So we wouldn't want to talk of utilization rates. I mean, rest assured that we said it's being ramped up' (Transcript page 12, Anish Ganatra)
  • Bypassing specific economic details or contract margin terms on the HFO pricing beyond high-level potential numbers (Transcript page 16, Anish Ganatra)

Numbers against the story

Management emphasized that gross profit and EBITDA margins were well protected despite high inflation; numbers show consolidated gross margin actually contracted by 186 bps YoY to 56.88% due to higher raw material expenses, but operating leverage in employee and other overheads drove operating EBITDA margin expansion by 176 bps YoY to 34.22%.

Sources

Notes written by gemini-3.8-flash from the documents above on 15 November 2026. They summarise what the company said and can contain mistakes: check the source passage before relying on a point. Not investment advice.